Company intelligence / Profile preview

Millennium Pharmaceuticals (now Takeda)

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Millennium's lead product, bortezomib (marketed as VELCADE), achieved market leadership in multiple myeloma and mantle cell lymphoma worldwide, with clinical and commercial success. Additional candidates in inflammatory diseases and oncology were in advanced stages pre-acquisition, including an anti-alpha4beta7 antibody and CCR9 inhibitor for inflammatory bowel disease advancing toward Phase III as of 2008.

Therapeutic areas: OncologyGastroenterology
Modalities: Small moleculeProteinMonoclonal antibody
Industry: Pharma

Beyond the preview

Go deeper on Millennium Pharmaceuticals (now Takeda).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Millennium Pharmaceuticals (now Takeda).

Explore the full profile